Skip to main content

Fiscal Wizard · Single-issue tearsheet

BDTX / Jun 21, 2026 Run #7427

BDTX

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Composite verdict

C 45.9 / 100
Bearish setup · Trend Following 15 drivers · 5 gates blocking
  • Relative Strength vs SPY
  • Aroon Oscillator
  • Keltner Channels
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 85th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $1.96Earnings power value $1.96Price $1.66

Trading below its asset value ($1.96/share) — deep value, but check for a melting balance sheet.

Fundamentals Strong

91.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
PEG 3
Earnings Yield 100
Asset Turnover 25
Free Cash Flow Yield 100

Technicals Bearish

0.0 / 100

Bearish setup leads (Relative Strength vs SPY, Aroon Oscillator, Keltner Channels); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 13
Rate of Change 15
Aroon Oscillator 16

Risk Gates

5 blocking 5 caution

5 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BDTX.